Non-responsiveness of transnational corporations to pharmaceutical needs

Commercial values overiding health needs
Inappropriate pharmaceutical products
Pharmaceutical transnational corporations are not responsive to the real drug needs of individual countries. Importation of pharmaceuticals is one of the fastest growing drains on hard foreign currency for developing countries. Some health ministries are spending over 50% of their budgets on drugs alone. In addition to cost, there are dangers of uncontrolled availability of potentially dangerous drugs. In many countries the great majority of drugs are available over the counter, without prescription. At the other end of the scale, are products which respond to consumer and commercial pressure rather than genuine medical needs, such as expensive cosmetic treatments for skin pigmentation and hormone treatments for height and weight. Somewhere in the middle, and related to the social responsibility of corporate activity, is the question why it is more attractive to devote the best of pharmaceutical research expertise to cures for ailments rather than prevention, ie vaccines and other form of prophylactic medicines.
In the case of inappropriate use of drugs, recent studies have disclosed, for example, that a fifth or North Yemen's drug imports and a quarter of all drugs sold in India are tonics, vitamins or indigestion tablets. Part of the flood of inessential drugs is due to the marketing practices of the international pharmaceutical industry. The WHO says that promotion activities of the drug manufacturers have created a demand greater than the actual needs. In Colombia, for example, the money spent on drug advertising is equivalent to more than half of the country's health budget. In Nepal, Brazil and some Central American countries there is one sales representative for every three doctors; this leads to overprescribing on a massive scale.
The best way to cope with these problems is to take control of drug production and distribution. This is why, in addition to urging the adoption of an essential list of basic drugs, WHO is encouraging an increase in generic prescribing (that is according to what drugs contain, rather than according to trade name) and local manufacture. This would enable countries to cut costs dramatically either by manufacturing the drugs themselves or by bulk-buying cheaper generic drugs on the world market.
International pharmaceutical companies employ tens of thousands of local people in developing countries. These operations generate billions of US$ in sales every year, including exports contributing to local trade balances. Pharmaceuticals are the most practical and cost-effective elements of medical technology. Drug companies tailor product lines to meet the needs of the specific populations they serve. The pharmaceutical industry is active in research and production of drugs for disease endemic in developing parts of the world. It is an active partner with government agencies and NGO's in making products available where they are needed. They are making significant progress in supplying medical professionals with literature about their products that is scientifically accurate and includes essential information on safety contraindications and side-effects where applicable.

If the markets of the international pharmaceutical industry are cut back drug companies will not be able to keep up the present volume of research into new drugs.

(E) Emanations of other problems